Aim: To evaluate the persistence with oral antidiabetic drug (OAD) treatment characterized by drug class, patient characteristics and severity of renal impairment (RI) in patients with type 2 diabetes (T2DM) in Japan. 
The Japan Diabetes Society recommends oral antidiabetic drugs (OADs), insulin and glucagon-like peptide-1 receptor agonists for patients with non-insulin-dependent type 2 diabetes mellitus (T2DM) with poorly controlled blood glucose levels after 2 to 3 months of diet and exercise. 5 The choice of OADs depends on disease status, with consideration of the characteristics and side effects of each drug.
Based on the underlying cause of T2DM, patients may be prescribed insulin-sensitizing agents (biguanides [BGs] ing the last decade in Japan. 6 In patients with T2DM and renal impairment (RI), all drugs, including OADs, and particularly those that affect renal metabolism and excretion, should be used according to their prescribing information with due consideration to the patient's glomerular filtration rate (GFR). 5 In general, all OADs can be used in patients with mild RI; however, treatment options for patients with moderate-to-severe chronic kidney disease or end-stage renal disease (ESRD) are limited because reduced GFR may lead to drug or metabolite accumulation and subsequent side effects. 7 Because T2DM requires long-term treatment, patients must remain adherent to and persistent with their prescribed OADs to optimize clinical benefits. 8 According to the World Health Organization, non-adherence to long-term medications for diseases such as hypertension, dyslipidaemia and diabetes is common, leading to compromised clinical outcomes and major economic consequences. 9 Patients' likelihood of maintaining adherence to and persistence with treatment is important, therefore, when choosing from a complex array of OADs. [8] [9] [10] [11] According to a literature review of six retrospective observational studies from the United States, Canada and Europe between January 2000 and November 2005, the mean estimated OAD persistence over 6 to 24 months was 56% (95% confidence interval
[CI] 46-66), with estimates ranging from 41% to 81%. 12 Although treatment adherence and persistence may be assessed as part of rigorously controlled clinical trials involving specific patient populations with diabetes, 13 reports of real-world OAD adherence and persistence rates are limited, particularly in Japan. 14, 15 To our knowledge, this is the first large-scale, real-world evaluation of treatment persistence, patient characteristics and severity of RI among classes of OADs in T2DM patients in Japan.
| MATERIALS AND METHODS

| Study objectives
The study objectives were to analyse treatment persistence and patient characteristics stratified by OAD class, individual DPP-4 inhibitors, RI category at index date, and lines of therapy (1, 2 and 3+). selected as the start date for data retrieval in this study to enable assessment of all seven DPP-4 inhibitors, which could be prescribed starting from a similar time point. In Japan, prescriptions are limited to 2 weeks for a period of 1 year after product launch; therefore, patients who visit the hospital every 2 weeks are able to access the necessary prescription. Seven DPP-4 inhibitors had entered the Japanese market in succession by July 2013. Multiple OADs in the first OAD prescription contributed to multiple index dates. Additional eligibility criteria were age ≥40 years at the time of T2DM diagnosis, no diagnosis of type 1 diabetes mellitus (ICD-10 code E10), no prescription for the OAD during the look-back period, and average of <92 days between hospital visits (excluding periods of inpatient hospitalization). Detailed information regarding the data source used in this study, study drugs prescribed to patients, and determination of index dates for comparison of drugs are provided in the Appendix S1.
| Study design and data source
| Analyses and statistical methods
Treatment persistence was defined as the duration of time from the index date to the first occurrence of discontinuation for each OAD class. OAD treatment was considered to be discontinued when there was a treatment gap of ≥30 days between two subsequent visits and days of drug supply.
For between-OAD class analysis, continuation was defined as continuing the same drug or switching drugs within a class; switching to another drug class was defined as discontinuation. Estimated GFR (eGFR) was calculated based on sex, age at index date, and the most recent serum creatinine value at the index date or during the lookback period using the following formula recommended by the Japanese Society of Nephrology, 18 where Cr is serum creatinine (mg/dL). ; ESRD). Comorbidities were defined by ICD-10 code (Table S1 , Appendix S1) and categorized by baseline RI at the index date (Table S2 , Appendix S1).
Descriptive statistics were used for patient demographics and α-GI, glinides and TZDs among patients with RI stage G4+ (12%, 2%, 6%, 16%, 18% and 3%) were lower than for those with RI stage G3 (31%, 24%, 33%, 34%, 32%, and 31%), respectively. The most common comorbidity at the index date was hypertension (68%); 18% of patients had RI. Comorbidities were more common among patients who were prescribed glinides and α-GIs, and less common among ), n (%) 3868 (15) 1592 (14) 838 (19) 530 (16) 429 (14) 252 (13) 227 (17) G2 (60 to <90 mL/min/1.73 m 2 ), n (%) 11 188 (44) 4877 (43) 2373 (55) 1446 (44) 1175 (37) 691 (37) 626 (48) G3 (30 to <60 mL/min/1.73 m 2 ), n (%) 7776 (31) 3566 (31) 1045 (24) 1090 (33) 1055 (34) 610 (32) 410 (31) G4+ (<30 mL/min/1.73 m 2 ), n (%) 2554 (10) 1411 (12) 67 (2) 208 (6) 488 (16) 337 (18) 43 (3) Comorbidities at index date, % ), n (%) 800 (16) 324 (14) 262 (14) 323 (8) 239 (12) 44 (15) 52 (12) G2 (60 to <90 mL/min/1.73 m 2 ), n (%) 2496 (50) 966 (41) 845 (46) 1104 (29) 764 (40) 148 (51) 203 (47) G3 (30 to <60 mL/min/1.73 m 2 ), n (%) 1479 (30) 774 (33) 538 (29) 1411 (37) 636 (33) 94 (32) 127 (29) G4+ (<30 mL/min/1.73 m 2 ), n (%) 223 (4) 311 (13) 205 (11) 985 (26) 276 (14) 7 (2) 54 (12) Comorbidities at index date, % Abbreviations: α-GI, α-glucosidase inhibitor; BG, biguanide; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; RI, renal impairment; SU, sulphonylurea; TZD, thiazolidinedione. a Previous treatment was defined as medications prescribed before, but not after, the index date. b Concomitant treatments were defined as medications prescribed with the first oral antidiabetic drug prescription at the index date or prescribed during the administration and were analysed as individual drugs. 
| Within-OAD class analyses: patient characteristics and DPP-4 inhibitor prescribing patterns
In total, 91 634 DPP-4 inhibitor index dates were identified, most commonly for sitagliptin, followed by linagliptin, vildagliptin, teneligliptin and alogliptin. Anagliptin and saxagliptin, the last two DPP-4 inhibitors to be launched, were not commonly prescribed ( Table 2 ). The mean age and ratio of men to women were similar across different DPP-4 inhibitor groups; however, within each group, prescribing pat- Table S4 ,
Appendix S1]).
| RI stage analyses: patient characteristics
The mean (SD) age of patients at RI stages G1, G2, G3 and G4+ was 65.6 (12.2), 69.5 (10.7), 75.0 (9.8) and 73.2 (10.8) years, respectively.
In general, HbA1c level decreased and the proportions of patients with each comorbidity increased with severity of RI (Table S2 , Appendix S1). Among patients without available serum creatinine data, age and proportions of patients with each comorbidity were in the range of values for patients at RI stages G2 and G3, except for myocardial infarction and diabetic foot. Figure 2A ). In the sensitivity analyses with a less stringent definition of persistence, treatment persistence was extended by~70% for all OAD classes; the relative order of persistence rates among drug classes was maintained ( Figure S1 , Appendix S1). Irrespective of the number of concomitant drugs (or line of treatment) at the index date, treatment persistence was longest for DPP-4 inhibitors and BGs and shortest for α-GIs and SUs ( Figure S2 , Appendix S1).
| Between-OAD class analyses: treatment persistence
| RI stage analyses: treatment persistence
In general, treatment persistence (assessed as time to discontinuation) for OADs was longest in patients at RI stage G2, similar between patients in stages G1 and G3, and shortest at stage G4+ ( Figure 2B ).
Persistence with each drug class varied by RI stage, and was longest for DPP-4 inhibitors at all RI stages, followed by BGs at RI stages G1
and G2 ( Figure 2C-F) .
| DISCUSSION
The results of the present retrospective, real-world database analysis
show that, among the OADs evaluated, DPP-4 inhibitors and BGs were the most frequently prescribed OAD classes, with the longest treatment persistence. These findings are similar to those from previous reports in Japan. 6, 19, 20 TZDs and glinides were the least frequently prescribed OADs, and treatment persistence was shortest for α-GIs and SUs. We believe treatment persistence is a result of several Considering patient baseline characteristics, the increasing severity of RI was consistent with ageing and higher rates of comorbidities. 23, 24 The younger average age of patients at RI stage G1 could explain why persistence appears lower than for those at stage G2 in our analysis 15 ; however, in general, treatment persistence rates declined with increasing severity of RI. This could be attributed to switching to other drugs without prescription restrictions in patients with increasing severity of RI, a reduced requirement for OADs because of a decline in blood sugar, and an increased risk of hypoglycaemia. 25 Although we observed similar (but longer) persistence for DPP-4 inhibitors and BGs compared with other OAD classes at RI stages G1 and G2, a longer persistence was observed for DPP-4 inhibitors than for BGs at RI stages G3 and G4+.
Evaluation of prescribing patterns showed that no concomitant
OADs were prescribed with DPP-4 inhibitors 55% of the time at the index date, suggesting that DPP-4 inhibitors were most frequently prescribed as first-line monotherapy. This observation is consistent with a study concluding that DPP-4 inhibitors were the most frequently prescribed OAD class during the last decade in Japan. 6 In the present study, BGs-which are widely endorsed as first-line treatment in Western countries 26, 27 -were used in younger patients with relatively stable renal function (G3, 24%; G4+, 2%). BGs such as metfor- α-GIs were prescribed to patients who were older, had reduced renal function, and more comorbidities. Many patients who were prescribed glinides at the index date had concomitant treatments, implying a tendency to prescribe this OAD class for patients with poor blood sugar control. 30 Notably, 19% of patients prescribed BGs and TZDs had comorbid heart failure despite contraindications. 5 Within the class of DPP-4 inhibitors, linagliptin was preferentially prescribed for patients at RI stage G4+ and for those who were older, had higher complication rates, and concomitant insulin use. Among patients prescribed other DPP-4 inhibitors at the index date, differences in baseline characteristics were negligible, indicating the potential for interchangeability of DPP-4 inhibitors in the sample. Further, more patients who were prescribed linagliptin as first-line treatment had baseline cardiac, renal and urinary disorders, an observation that was also reported in a previous post-marketing surveillance study. 31 Linagliptin is excreted via the biliary route rather than the renal route like other DPP-4 inhibitors; therefore, it can be prescribed regardless of RI stage. 32 Teneligliptin, which has the second highest rate of biliary excretion (34%), 33 was also frequently prescribed in patients with RI stage G4+. Notably, teneligliptin-treated patients had higher average eGFRs than linagliptin-treated patients. Since prescription of DPP-4 inhibitors has increased rapidly in Japan, the study period is likely to impact this type of real-world data analysis. Tanabe et al 14 reported that DPP-4 inhibitors were stopped for 2 years in~80% of cases in a study using the same database The present study has several strengths, including its real-world setting, the data evaluation from a recognized, large database covering 300 Japanese hospitals providing care for acute-phase diseases to >20 million patients, 34 ; however, their use may be restricted in other countries. This might be partly attributable to differences in approach while formulating treatment guidelines, 38 the health insurance reimbursement system, as well as differences in diabetes pathophysiology. 39, 40 Nevertheless, the results reflect a long-term, real-world scenario in a large number of patients from numerous centres and provide a comprehensive description of the characteristics of present treatment with OADs in Japanese patients with T2DM.
Overall, DPP-4 inhibitors were the most frequently prescribed OAD class, accounting for half of the index dates, followed by BGs, SUs, α-GIs, glinides and TZDs. Treatment persistence was longest for DPP-4 inhibitors and BGs. Notably, persistence was highest with DPP-4 inhibitors in patients with severely decreased renal function.
Most OADs were prescribed appropriately by practitioners in Japan;
however, contrary to recommendations, BGs were prescribed for patients at RI stage G3 and G4, and SUs and TZDs for patients at stage G4. We believe that the appropriate use of OADs can be improved to achieve the goals of long-term, effective treatment of patients with
T2DM. An open question is whether the higher persistence seen for certain classes was associated with improvements in health outcomes. 
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